Forte Biosciences (FBRX) Gains from Investment Securities (2016 - 2017)
Forte Biosciences (FBRX) posted quarterly Gains from Investment Securities of $22000.0 for Q2 2017, up 181.48% year-over-year from $7815.8 in Q2 2016, and up 137.29% quarter-over-quarter from -$59000.0 in Q1 2017.
Powered by 
Analysis
Forte Biosciences (FBRX) Gains from Investment Securities (2016 - 2017) Analysis & Trends
Forte Biosciences (FBRX) has reported Gains from Investment Securities for 2 consecutive years, with $22000.0 the latest figure, recorded in Q2 2017.
- In Q2 2017, Gains from Investment Securities rose 181.48% year-over-year to $22000.0; the TTM figure through Dec 2017 stood at -$37000.0 (up 26.0% YoY), while the FY2017 annual figure was -$37000.0, up 26.0% from the prior year.
- Gains from Investment Securities advanced to $22000.0 in Q2 2017 per FBRX's latest filing, from -$59000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $22000.0 in Q2 2017 and bottomed at -$59000.0 in Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | 22,000.00 |
| Mar 31, 2017 | -59,000.00 |
| Dec 31, 2016 | -32,000.00 |
| Sep 30, 2016 | 11,000.00 |
| Jun 30, 2016 | -27,000.00 |
| Mar 31, 2016 | -2,000.00 |